Compare ACU & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | PLX |
|---|---|---|
| Founded | 1867 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.6M | 168.4M |
| IPO Year | 1994 | 1996 |
| Metric | ACU | PLX |
|---|---|---|
| Price | $47.86 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | $12.00 |
| AVG Volume (30 Days) | 11.0K | ★ 568.8K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 1.63 | N/A |
| EPS | ★ 0.24 | 0.22 |
| Revenue | ★ $196,541,816.00 | $52,744,000.00 |
| Revenue This Year | $5.67 | $36.81 |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $198.17 | ★ $10.09 |
| Revenue Growth | ★ 1.05 | N/A |
| 52 Week Low | $35.50 | $1.36 |
| 52 Week High | $47.56 | $3.19 |
| Indicator | ACU | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 74.41 | 65.41 |
| Support Level | $40.57 | $2.06 |
| Resistance Level | N/A | $2.42 |
| Average True Range (ATR) | 1.58 | 0.09 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 86.58 | 88.89 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.